AstraZeneca PLC (AZN) Valuation
Historical valuation analysis based on 1281 data points (2021-09-10 to 2026-10-16)
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% o...
AstraZeneca PLC (AZN) currently trades at a P/E ratio of 25.09 (historical range: 11.80–1968.80, median: 40.91), placing it at the 35th percentile — below its historical average, P/S ratio of 4.37 (range: 1.86–5.93, 36th percentile — below its historical average), EV/EBITDA of 19.87 (range: 9.64–84.71, 35th percentile).
Over the historical period (2021-09-10 to 2026-10-16), AstraZeneca PLC's P/E ratio has contracted by 98% over the observed period (from an average of 911.9 to 22.7).
AstraZeneca PLC trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 25.09 | 40.91 | 35th | below its historical average |
| P/S Ratio | 4.37 | 4.60 | 36th | below its historical average |
| EV/EBITDA | 19.87 | 25.89 | 35th | below its historical average |
| FCF Yield | 4.16% | 4.74% | 17th | expensive relative to its history |
AstraZeneca PLC (AZN) Valuation & P/E History
AstraZeneca PLC (AZN) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $164.21 with a market capitalization of $254.7 billion. This page provides historical valuation analysis for AZN based on 1281 data points covering 2021-09-10 to 2026-10-16. The P/E ratio of 25.09 is below the historical median of 40.91, placing AZN at the 35th percentile of its valuation range. The P/S ratio of 4.37 compares to a median of 4.60.
AZN Valuation Metrics & Historical Range
The valuation table above shows AstraZeneca PLC's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether AZN is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests AZN is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for AstraZeneca PLC.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is AZN Overvalued or Undervalued?
AstraZeneca PLC trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 35 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive AZN is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full AZN analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.AZN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.